Racura Oncology Ltd has released a press release.
Racura Enters Underwriting Agreement for Options
Filed with ASX · · 5 pages · English
6ix is checking which company filed this.
Story so far
Earlier from Racura Oncology
- Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial
- CPACS Trial Cleared to Escalate to Next RC220 Dose Level
- (E,E)-bisantrene Discovered to Function via Silencing of c-MYC Expression
- March 2026 Quarterly Activity Report and Appendix 4C
- Racura presents MYC silencing data at AACR 2026
Later from Racura Oncology
- Emerging Companies Specialist Invests in Racura
- Racura raised $34.3m to Advance Three Oncology Trials
- Racura Treats First Patient in HARNESS-1 Lung Cancer Trial
- Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung Cancer
- Bellberry Ethics Approval Activates New HARNESS Trial Sites
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology